Global Pharmaceutical Risk-SharingAgreement Trends in 2011 and 2012:Slowing Down?Ando G, Izmirlieva M, Honore A (IHS, Lond...
Upcoming SlideShare
Loading in …5
×

Global pharmaceutical risk-sharing agreement trends in 2011 and 2012: Slowing down

1,539 views
1,414 views

Published on

IHS Healthcare and Pharma research on risk-sharing agreement trends. Poster for ISPOR

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,539
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
52
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Global pharmaceutical risk-sharing agreement trends in 2011 and 2012: Slowing down

  1. 1. Global Pharmaceutical Risk-SharingAgreement Trends in 2011 and 2012:Slowing Down?Ando G, Izmirlieva M, Honore A (IHS, London, United Kingdom)Background • isk-sharing agreements are often accompanied by significant R confidentiality, and there are immediate limitations that wereWith austerity measures continuing to limit healthcare budgets recognised from the outset over precisely how much informationaround the world, healthcare payers are under increasing pressure and detail could be elucidated from each agreement, althoughto ensure that medical technologies are utilised in the most cost- primary research was designed to capture as much informationefficient manner. This is particularly true in reimbursement as possible.decisions and clinical guidelines for new, innovative, andpotentially expensive therapies. In this climate, pharmaceuticalcompanies have adopted increasingly creative strategies to Resultsachieve at least some form of reimbursement for their new In the period of review (May 2011–May 2012), 32 new risk-sharingproducts, including so-called “risk-sharing agreements.” agreements were found, an average of 2.6 per month, which is roughly in line with the rate found in previous years. The total forRisk-sharing agreements are now a well-established channel the period January 2010–June 2011 included 45 agreements, orthrough which reimbursement negotiations can be conducted in 2.5 per month.many key markets. After a period of market expansion of theseagreements in 2005-10, there have been significant questionmarks over precisely how effective they are in establishing efficientclinical decision making.IHS Global Insight has published ISPOR research examining thelatest global trends in pharmaceutical risk-sharing agreementsthree times. This research has generally shown the expansion ofrisk-sharing agreements both in terms of outcomes-based andfinancial-based arrangements, and also from developed todeveloping markets. This is an examination of the latest data up tothe end of May 2012.ObjectivesWhilst recognising that risks-sharing agreements represent animportant market-access strategy, the objective of this researchwas to examine if the marked expansion in number of risk-sharing The number of new drugs with risk-sharing agreements attachedagreements through 2005-10 is still continuing, or if there has to them actually declined, and most new agreements are beingbeen a gradual levelling off across the world. negotiated for drugs that already have one in place.The objective was subdivided to examine: The majority of agreements tend to be finance based (n=24, or 75%), although new performance-based agreements (n=7, or• hich types of risk-sharing agreements are increasing or W 12%) continue to emerge, including in emerging markets. decreasing in number. The majority of agreements (n=21, or 65%) continue to focus on• Which therapeutic areas are most prone to these agreements. the oncology arena, with other therapeutic areas associated with biologics, such as rheumatoid arthritis, age-related macular• Which geographic markets are evolving in this area. degeneration, and multiple sclerosis, as well as a variety of orphan diseases, also represented.Methods Agreements were signed in the United Kingdom (n=20, 62%), Italy• econdary research was conducted examining reimbursement S (n=7), Spain, Portugal, Germany, Netherlands, and Poland. decisions around the world, with a special focus on Australia, Belgium, Canada, China, France, Germany, Hungary, Italy, Netherlands, New Zealand, Poland, Spain, United Kingdom, Conclusions and United States. Although risk-sharing continues to be a routine part of market access in many countries, there appears to be a notable “levelling• ources were taken from IHS Global Insight’s Global Risk- S off” of the rapid expansion of this strategy. This is relatively Sharing Agreement database, as well as regulatory websites unsurprising as it reaches a natural plateau, but is still notable around the world, academic research, press releases, news against the background of ongoing global austerity. It appears wires, official announcements, and conference presentations. governments are forsaking more complicated pharmaco- economic strategies in general, and risk-sharing agreements in• his was supplemented by primary research with payers, T particular, as a means of cost containment. Perhaps this is government agencies, and HTA organisations through because of the uncertainty surrounding their efficacy in this regard. interviews in native languages to understand the role risk- sharing agreements have—or have not—played in their respective markets. FOR MORE INFORMATION ABOUT IHS GLOBAL INSIGHT HEALTHCARE PHARMACEUTICAL SERVICES www.ihs.com/healthcare and www.ihs.com/healthcareblog Please email: gustav.ando@ihs.com for any questions related to this poster

×